1. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Harrison, C.; Rampal, R. K.; Gupta, V.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.; Vannucchi, A.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M. J.; Al-Ali, H. K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Akhani, S.; Muñoz-Carerras, R.; Sheykin, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS. (23rd June 2022) Authors: Meeuwes, F. O.; Brink, M.; Van der Poel, M. W.; Kersten, M. J.; Wondergem, M. J.; Mutsaers, P. G.; Böhmer, L. H.; Woei-A-Jin, F. J. S. H.; Visser, O.; Oostvogels, R.; Jansen, P. M.; Plattel, W. J.; Huls, G. A.; Vermaat, J. S.; Nijland, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗